Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation

Go Makimoto; Tatsuya Nishi; Keita Kawakado; Tomoka Nishimura; Tomoki Tamura; Kenichiro Kudo; Shoichi Kuyama

doi:10.2169/internalmedicine.4429-20

Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation

Go Makimoto, Tatsuya Nishi, Keita Kawakado, Tomoka Nishimura, Tomoki Tamura, Kenichiro Kudo, Shoichi Kuyama

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.

Original language	English
Pages (from-to)	2161-2164
Number of pages	4
Journal	Internal Medicine
Volume	59
Issue number	17
DOIs	https://doi.org/10.2169/internalmedicine.4429-20
Publication status	Published - Sept 1 2020
Externally published	Yes

Keywords

Desensitization
Epidermal growth factor receptor
Non-small-cell lung cancer
Osimertinib

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.4429-20

Fingerprint

Dive into the research topics of 'Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation'. Together they form a unique fingerprint.

Cite this

Makimoto, G., Nishi, T., Kawakado, K., Nishimura, T., Tamura, T., Kudo, K., & Kuyama, S. (2020). Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation. Internal Medicine, 59(17), 2161-2164. https://doi.org/10.2169/internalmedicine.4429-20

Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation. / Makimoto, Go; Nishi, Tatsuya; Kawakado, Keita et al.
In: Internal Medicine, Vol. 59, No. 17, 01.09.2020, p. 2161-2164.

Research output: Contribution to journal › Article › peer-review

Makimoto, G, Nishi, T, Kawakado, K, Nishimura, T, Tamura, T, Kudo, K & Kuyama, S 2020, 'Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation', Internal Medicine, vol. 59, no. 17, pp. 2161-2164. https://doi.org/10.2169/internalmedicine.4429-20

@article{4476abedb8034c13b30312742b64c9fa,

title = "Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation",

abstract = "Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.",

keywords = "Desensitization, Epidermal growth factor receptor, Non-small-cell lung cancer, Osimertinib",

author = "Go Makimoto and Tatsuya Nishi and Keita Kawakado and Tomoka Nishimura and Tomoki Tamura and Kenichiro Kudo and Shoichi Kuyama",

year = "2020",

month = sep,

day = "1",

doi = "10.2169/internalmedicine.4429-20",

language = "English",

volume = "59",

pages = "2161--2164",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "17",

}

TY - JOUR

T1 - Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation

AU - Makimoto, Go

AU - Nishi, Tatsuya

AU - Kawakado, Keita

AU - Nishimura, Tomoka

AU - Tamura, Tomoki

AU - Kudo, Kenichiro

AU - Kuyama, Shoichi

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.

AB - Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.

KW - Desensitization

KW - Epidermal growth factor receptor

KW - Non-small-cell lung cancer

KW - Osimertinib

UR - http://www.scopus.com/inward/record.url?scp=85090285602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090285602&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.4429-20

DO - 10.2169/internalmedicine.4429-20

M3 - Article

C2 - 32461525

AN - SCOPUS:85090285602

SN - 0918-2918

VL - 59

SP - 2161

EP - 2164

JO - Internal Medicine

JF - Internal Medicine

IS - 17

ER -

Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this